Oppenheimer Lifts Numbers on Endologix (ELGX) On Higher Nellix Expectations

March 14, 2012 7:50 AM EDT
Get Alerts ELGX Hot Sheet
Price: $0.22 --0%

Rating Summary:
    7 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Oppenheimer raised estimates and its price target on Outperform-rated Endologix (NASDAQ: ELGX) from $14 to $17 following meetings with three surgeons on their experiences with ELGX's Nellix abdominal aortic aneurysm (AAA) system, slated for European approval mid-year. The three surgeons were among the initial clinical investigators of Nellix.

"Based on our extensive conversations, we're increasingly confident that Nellix will be viewed as a front-line product in the AAA market," the analyst commented. "We are raising our sales estimates for '13 and beyond and price target to $17, and see the stock as well positioned here on any dips ahead of several 2H12 key catalysts."

Oppenheimer raised FY13 revenues from $137.1 million to $138.5 million and EPS from ($0.16) to $0.06.

For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.

Shares of Endologix closed at $13.39 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change